Psilocybin and alcohol use disorder: what the studies show
A randomized study reported fewer heavy drinking days with psilocybin-assisted psychotherapy in 2022. A smaller 2025 trial after withdrawal treatment did not find significant differences in its primary outcomes. These studies address different clinical questions; reading them together helps avoid turning an encouraging result into a universal treatment claim.
Selected research interpretation, not a systematic review or personal treatment recommendation. No independent clinical review is claimed. Do not change alcohol treatment or prescribed medication based on this page.
Alcohol studies compared by design and endpoint
A reduction in heavy drinking days and prevention of relapse after withdrawal are different endpoints. The table keeps the study population, comparator and follow-up attached to each result.
| Report and population | Design and sample | Endpoint and finding | Interpretation limit |
|---|---|---|---|
| Swiss relapse-prevention trial · 2025 Alcohol use disorder following recent withdrawal treatment PubMed 40144690NCT04141501 | Randomized placebo-controlled trial; one supervised session with brief psychotherapy 37 participants in the four-week analysis: 18 psilocybin, 19 placebo | Primary comparisons inconclusive Abstinence and average alcohol consumption at four weeks Neither primary comparison was significant: abstinence p=0.55; alcohol use p=0.51. Six-month comparisons also showed no significant group difference. | Small sample; a different population, dosing schedule and psychotherapy programme from the 2022 trial. The result does not establish equivalence or rule out a clinically relevant effect. |
| Bogenschutz et al. · 2022 Adults with alcohol dependence; two US academic centres PubMed 36001306Tracker record and citations NCT02061293 | Randomized trial; two psilocybin or diphenhydramine sessions alongside 12 weeks of psychotherapy 95 randomized; 93 received study medication and entered the primary analysis | Primary endpoint favored psilocybin Percentage of heavy drinking days across 32 weeks after the first session 9.7% with psilocybin versus 23.6% with active placebo: 13.9 percentage points fewer heavy drinking days (95% CI 3.0–24.7), p=0.01. | Participants could often identify their allocation. Results concern the combined supervised intervention and selected participants, not psilocybin alone or every person with alcohol use disorder. |
| Bogenschutz et al. · 2015 pilot Ten volunteers with alcohol dependence PubMed 25586396Tracker record and citations | Single-group proof-of-concept study; supervised sessions with motivational and preparatory therapy 10 volunteers; no randomized comparison group | Preliminary uncontrolled finding Drinking and abstinence over treatment and follow-up The investigators observed increased abstinence after dosing, with gains broadly maintained through 36 weeks. | Without a concurrent control, improvement cannot be attributed specifically to psilocybin. This preliminary report supported further trials rather than confirming efficacy. |
Export 2 indexed references as BibTeXRIS for citation managers
Exports include visible indexed records only. DOI and PubMed links remain available when a record is absent or withheld.
Why the trial results should not be treated as interchangeable
The 2022 study assessed drinking over a prolonged follow-up in a community-recruited sample. The 2025 study examined relapse following withdrawal treatment. Differences in initial drinking status, treatment intensity, session number and outcomes prevent a simple direct comparison.
A statistically significant result does not show that every participant benefited. A nonsignificant result does not establish that two interventions are equivalent. Read the effect estimate, confidence interval and analysis population before deciding how much weight to give either finding.
Both randomized programmes included psychotherapy. Their comparisons evaluate interventions within those programmes; they do not isolate an effect of psilocybin without support. The uncontrolled pilot is useful historical context but cannot resolve this causal question.
See the research-reading checklist for endpoints, confidence intervals, blinding and study status.
Safety findings and eligibility need their own assessment
Trial participants are screened, monitored and followed under a defined protocol. A small study with few serious events cannot establish safety for rare harms, excluded populations or unsupervised use. Safety reporting also needs denominators, follow-up duration and a distinction between an event occurring during a study and one attributed to the intervention.
Alcohol withdrawal and medication decisions require appropriate clinical assessment. Use the original reports and NCCIH's research and safety overview to understand context. Participation is governed by each study's eligibility rules and contacts, not this website.
Common research questions
Does this establish that psilocybin treats alcohol use disorder?
These selected studies provide mixed evidence for defined supervised interventions. They do not establish effectiveness across all populations or care settings. The table identifies what each study tested.
Is abstinence the same as fewer heavy drinking days?
No. Complete abstinence, time to relapse, average consumption and heavy drinking days describe different aspects of drinking. A favourable result on one cannot be substituted for another.
Where can I find studies accepting participants?
Start with the alcohol use disorder trial collection and recruiting trial finder. Confirm status, location and eligibility directly with the registry and study team; a registration does not guarantee a place.
Selection, corrections and sources
This guide selects an early pilot and two randomized reports to illustrate distinct alcohol research questions. It is not an exhaustive search, formal risk-of-bias assessment, meta-analysis or guideline. Original annotations were checked against primary bibliographic records on 7 October 2026; no source abstracts are redistributed.
The 2022 article has a published correction concerning race and ethnicity counts. Consult the corrected original when examining its participant characteristics.
These reports may not represent every subsequent publication. Check the live alcohol literature search for newer records and the editorial policy for source selection and corrections. Related resources: depression evidence, dataset methods and reuse, evidence map.